Tracking Cathie Wood: Loading up on Precision Medicine & Defense Tech, Slashing Crypto and AI Compute

On Monday, September 14, 2026, U.S. equities faced broad-based selling pressure to start the week. The S&P 500 closed at 7,619.98 (down 0.48%), the Nasdaq Composite at 26,186.41 (down 0.56%), and the Dow Jones Industrial Average at 52,421.20 (down 0.29%), with cautious market sentiment prevailing across the board.

Symbols

Against this backdrop, ARK Invest's trading activity on the day reflected a distinct "offense-meets-defense" strategic posture — buying into precision medicine, defense tech, and social platforms against the broader market weakness, while executing large-scale repositioning across crypto assets, AI compute infrastructure, and select genomics names. The overall message may be that Cathie Wood is actively reducing near-term volatility exposure and concentrating firepower into higher-conviction, longer-duration themes.

Buy: Contrarian Conviction in Precision Medicine and Hard-Tech Moats

$Ionis Pharmaceuticals (IONS.US)$ was the largest buy of the day, with 166,585 shares added. Ionis commands a proprietary antisense oligonucleotide (ASO) platform spanning neurology, cardiovascular disease, and rare conditions — ARK's sizable add-on may reflect conviction in the platform's scarcity value and potential pipeline catalysts, possibly positioning it as a core holding within the precision medicine theme.

$Guardant Health (GH.US)$ saw 39,558 shares added. As a leader in liquid biopsy and non-invasive cancer early detection, Guardant continues to expand its commercial footprint. This incremental buy likely reflects ARK's continued belief in the long-term structural opportunity of rising cancer screening penetration rates.

$AeroVironment (AVAV.US)$ received an addition of 29,016 shares. Specializing in tactical unmanned aerial systems and loitering munitions, AeroVironment stands to benefit from accelerating global defense modernization and the rapid integration of drone warfare. ARK's move here may represent a targeted play on the "AI-enabled defense" theme.

$Meta Platforms (META.US)$ was added to by 10,997 shares. With Meta continuing to invest heavily in AI infrastructure and its AR/VR ecosystem, its massive social graph moat combined with generative AI deployment could fit squarely into ARK's thesis on next-generation internet platforms.

Sell: Compressing Crypto Exposure, Trimming AI Compute and Genomics

$ARK 21Shares Bitcoin ETF (ARKB.US)$ saw the most significant reduction of the day, with 1,528,953 shares sold. This move likely reflects a deliberate reduction of crypto allocation across ARK's portfolios — possibly tied to cross-fund liquidity management — rather than any change in the firm's long-term view on Bitcoin.

$10x Genomics (TXG.US)$ was reduced by 322,723 shares. Despite its unique technological moat in spatial genomics, 10x Genomics has faced near-term commercialization headwinds. This significant reduction may be part of portfolio optimization and a selective trimming of positions where near-term catalysts are less clear.

$Bitmine Immersion Technologies (BMNR.US)$ was trimmed by 153,881 shares, $Circle (CRCL.US)$ by 142,350 shares, $Coinbase (COIN.US)$ by 36,628 shares, and $Bullish (BLSH.US)$ by 18,280 shares. The simultaneous reduction across multiple crypto-related names alongside the ARKB sale paints a clear picture: compressing total crypto exposure was the dominant operational theme of the day, likely as part of a broader cross-asset risk rebalancing exercise.

$Tempus AI (TEM.US)$ was reduced by 87,027 shares, $CoreWeave (CRWV.US)$ by 64,923 shares, $Palantir (PLTR.US)$ by 34,548 shares, $Advanced Micro Devices (AMD.US)$ by 20,470 shares, and $Amazon (AMZN.US)$ by 20,000 shares. The coordinated trimming of multiple AI and compute infrastructure names suggests ARK may be pruning positions where valuations are seen as having already priced in near-term expectations, freeing up capital for redeployment into higher-conviction ideas.

$Iridium Communications (IRDM.US)$ was reduced by 54,500 shares, $Shopify (SHOP.US)$ by 49,844 shares, $Alphabet-C (GOOG.US)$ by 38,273 shares, and $Teledyne Technologies (TDY.US)$ by 5,181 shares. These reductions span satellite communications, e-commerce, and digital advertising — the breadth of the selling suggests a systemic portfolio optimization, concentrating capital toward highest-conviction core positions.

$GeneDx Holdings (WGS.US)$ was reduced by 22,586 shares, $Twist Bioscience (TWST.US)$ by 15,138 shares, $Illumina (ILMN.US)$ by 9,327 shares, $Natera (NTRA.US)$ by 7,805 shares, and $Brera Holdings (SLMT.US)$ by 3,991 shares. Within the precision medicine and genomics sector, ARK's simultaneous large buys in Ionis and Guardant alongside these reductions point to a clear intra-sector rotation — consolidating into preferred names while trimming peripheral or lower-conviction positions.

Go to Markets> Smart Money Tracker to track Cathie Wood's portfolio. Tap "Alerts" to receive real-time buy and sell signals. Update the app to try it now>>

96K Views